A recent study (C Belza et al. JPEN 2019; https://doi.org/10.1002/jpen.1692) showed that SMOFlipid reduced the frequency of cholestasis in intestinal failure patients. Thanks to Kipp Ellsworth for reference.
Methods
This was a retrospective cohort study of infants with IF with a minimum follow‐up of 12 months in 2008–2016. Patients were stratified into 2 groups: group 1 received SMOFlipid; group 2 was a historical cohort who received Intralipid. The primary outcome was liver function evaluated using conjugated bilirubin (CB) levels…
Results
Thirty‐seven patients were evaluated (17 = SMOFlipid, 20 = Intralipid). SMOFlipid patients were less likely to reach CB of 34 (24% vs 55%, P = 0.05), 50 µmol/L (11.8% vs 45%; P = 0.028), and did not require Omegaven (0% vs 30%; P = 0.014). CB level at 3 months after initiation of parenteral nutrition (PN) was lower in patients receiving SMOFlipid (0 vs 36 µmol/L; P = 0.01). Weight z‐scores were improved for patients receiving SMOFlipid at 3 months (−0.932 vs −2.092; P = 0.028) and 6 months (−0.633 vs −1.614; P = 0.018).
Related blog posts:
- Double-Blind Randomized SMOFlipid Study
- Nutrition Week: SMOFlipid
- Optimizing lipids to minimize cholestasis
- Neonatal Nutrition Lecture -What We Know Right Now …
- Improving Outlook in Neonatal Nutrition (Part 1)
- Current Mortality from Being Born Premature | gutsandgrowth
- Visual Acuity and LCPUFA | gutsandgrowth
- Weight Gain in Preemies, Neurodevelopmental Outcomes, and Reverse Causation
- Medical Progress for Intestinal Failure Associated Liver Disease
Crater Lake, OR
Pingback: Does SMOFlipid Improve Neurocognitive Outcomes? | gutsandgrowth
Pingback: Parenteral Nutrition: “The Scar Remains” | gutsandgrowth